nodes	percent_of_prediction	percent_of_DWPC	metapath
Venlafaxine—ABCG2—Mycophenolate mofetil—psoriasis	0.047	0.0764	CbGbCtD
Venlafaxine—CYP2B6—Cholecalciferol—psoriasis	0.0382	0.0619	CbGbCtD
Venlafaxine—ABCG2—Hydrocortisone—psoriasis	0.0377	0.0613	CbGbCtD
Venlafaxine—ABCG2—Cyclosporine—psoriasis	0.0356	0.0579	CbGbCtD
Venlafaxine—CYP2D6—Hydroxyurea—psoriasis	0.0304	0.0494	CbGbCtD
Venlafaxine—CYP2C19—Cholecalciferol—psoriasis	0.0242	0.0394	CbGbCtD
Venlafaxine—ABCG2—Dexamethasone—psoriasis	0.0235	0.0381	CbGbCtD
Venlafaxine—CYP3A4—Calcitriol—psoriasis	0.0228	0.0369	CbGbCtD
Venlafaxine—CYP2C9—Cholecalciferol—psoriasis	0.0202	0.0327	CbGbCtD
Venlafaxine—ABCG2—Methotrexate—psoriasis	0.0189	0.0306	CbGbCtD
Venlafaxine—CYP2D6—Cholecalciferol—psoriasis	0.0184	0.0299	CbGbCtD
Venlafaxine—CYP3A4—Methoxsalen—psoriasis	0.0177	0.0287	CbGbCtD
Venlafaxine—ABCB1—Mycophenolate mofetil—psoriasis	0.017	0.0275	CbGbCtD
Venlafaxine—CYP2C19—Prednisone—psoriasis	0.0168	0.0273	CbGbCtD
Venlafaxine—CYP2B6—Dexamethasone—psoriasis	0.0165	0.0268	CbGbCtD
Venlafaxine—CYP2C19—Cyclosporine—psoriasis	0.0159	0.0259	CbGbCtD
Venlafaxine—ABCB1—Betamethasone—psoriasis	0.0146	0.0236	CbGbCtD
Venlafaxine—ABCB1—Prednisolone—psoriasis	0.0144	0.0233	CbGbCtD
Venlafaxine—ABCB1—Hydrocortisone—psoriasis	0.0136	0.0221	CbGbCtD
Venlafaxine—ABCB1—Prednisone—psoriasis	0.0136	0.022	CbGbCtD
Venlafaxine—CYP2C9—Cyclosporine—psoriasis	0.0132	0.0215	CbGbCtD
Venlafaxine—ABCB1—Cyclosporine—psoriasis	0.0129	0.0209	CbGbCtD
Venlafaxine—CYP2D6—Cyclosporine—psoriasis	0.0121	0.0197	CbGbCtD
Venlafaxine—CYP3A4—Cholecalciferol—psoriasis	0.0117	0.019	CbGbCtD
Venlafaxine—CYP2C19—Dexamethasone—psoriasis	0.0105	0.017	CbGbCtD
Venlafaxine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0102	0.0165	CbGbCtD
Venlafaxine—CYP3A4—Triamcinolone—psoriasis	0.0102	0.0165	CbGbCtD
Venlafaxine—CYP2C9—Dexamethasone—psoriasis	0.00872	0.0142	CbGbCtD
Venlafaxine—CYP3A4—Betamethasone—psoriasis	0.00872	0.0142	CbGbCtD
Venlafaxine—CYP3A4—Prednisolone—psoriasis	0.0086	0.014	CbGbCtD
Venlafaxine—ABCB1—Dexamethasone—psoriasis	0.00846	0.0137	CbGbCtD
Venlafaxine—CYP3A4—Hydrocortisone—psoriasis	0.00815	0.0132	CbGbCtD
Venlafaxine—CYP3A4—Prednisone—psoriasis	0.00812	0.0132	CbGbCtD
Venlafaxine—CYP2D6—Dexamethasone—psoriasis	0.00798	0.0129	CbGbCtD
Venlafaxine—CYP3A4—Cyclosporine—psoriasis	0.0077	0.0125	CbGbCtD
Venlafaxine—ABCB1—Methotrexate—psoriasis	0.0068	0.011	CbGbCtD
Venlafaxine—CYP3A4—Dexamethasone—psoriasis	0.00507	0.00823	CbGbCtD
Venlafaxine—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00176	0.0552	CbGpPWpGaD
Venlafaxine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00133	0.0417	CbGpPWpGaD
Venlafaxine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00122	0.0384	CbGpPWpGaD
Venlafaxine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00121	0.038	CbGpPWpGaD
Venlafaxine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00114	0.0358	CbGpPWpGaD
Venlafaxine—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00109	0.0342	CbGpPWpGaD
Venlafaxine—NPY1R—G alpha (i) signalling events—HCAR2—psoriasis	0.000836	0.0262	CbGpPWpGaD
Venlafaxine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000825	0.0259	CbGpPWpGaD
Venlafaxine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000759	0.0238	CbGpPWpGaD
Venlafaxine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000752	0.0236	CbGpPWpGaD
Venlafaxine—NPY1R—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000664	0.0208	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—IL22—psoriasis	0.000646	0.0202	CbGpPWpGaD
Venlafaxine—NPY1R—Peptide ligand-binding receptors—CCL20—psoriasis	0.000514	0.0161	CbGpPWpGaD
Venlafaxine—NPY1R—GPCR ligand binding—HCAR2—psoriasis	0.000506	0.0159	CbGpPWpGaD
Venlafaxine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000496	0.0155	CbGpPWpGaD
Venlafaxine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000453	0.0142	CbGpPWpGaD
Venlafaxine—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000447	0.014	CbGpPWpGaD
Venlafaxine—NPY1R—G alpha (i) signalling events—CCL20—psoriasis	0.000434	0.0136	CbGpPWpGaD
Venlafaxine—ABCG2—Iron uptake and transport—CP—psoriasis	0.000413	0.013	CbGpPWpGaD
Venlafaxine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000367	0.0115	CbGpPWpGaD
Venlafaxine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000345	0.0108	CbGpPWpGaD
Venlafaxine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000343	0.0107	CbGpPWpGaD
Venlafaxine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000338	0.0106	CbGpPWpGaD
Venlafaxine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000315	0.00987	CbGpPWpGaD
Venlafaxine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000312	0.00979	CbGpPWpGaD
Venlafaxine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000311	0.00974	CbGpPWpGaD
Venlafaxine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000308	0.00966	CbGpPWpGaD
Venlafaxine—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000293	0.00919	CbGpPWpGaD
Venlafaxine—NPY1R—GPCR downstream signaling—HCAR2—psoriasis	0.000286	0.00896	CbGpPWpGaD
Venlafaxine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000278	0.0087	CbGpPWpGaD
Venlafaxine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000267	0.00838	CbGpPWpGaD
Venlafaxine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000265	0.00829	CbGpPWpGaD
Venlafaxine—NPY1R—GPCR ligand binding—CCL20—psoriasis	0.000263	0.00824	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling by GPCR—HCAR2—psoriasis	0.00026	0.00814	CbGpPWpGaD
Venlafaxine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000255	0.008	CbGpPWpGaD
Venlafaxine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000253	0.00794	CbGpPWpGaD
Venlafaxine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000236	0.0074	CbGpPWpGaD
Venlafaxine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000234	0.00735	CbGpPWpGaD
Venlafaxine—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.000212	0.00663	CbGpPWpGaD
Venlafaxine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000208	0.00653	CbGpPWpGaD
Venlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000206	0.00646	CbGpPWpGaD
Venlafaxine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000203	0.00637	CbGpPWpGaD
Venlafaxine—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000195	0.00612	CbGpPWpGaD
Venlafaxine—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000192	0.00603	CbGpPWpGaD
Venlafaxine—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000186	0.00584	CbGpPWpGaD
Venlafaxine—SLC6A2—NRF2 pathway—TGFA—psoriasis	0.000182	0.00571	CbGpPWpGaD
Venlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000167	0.00523	CbGpPWpGaD
Venlafaxine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000165	0.00516	CbGpPWpGaD
Venlafaxine—SLC6A3—NRF2 pathway—TGFA—psoriasis	0.000161	0.00505	CbGpPWpGaD
Venlafaxine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000159	0.00497	CbGpPWpGaD
Venlafaxine—SLC6A4—Monoamine Transport—TNF—psoriasis	0.000158	0.00494	CbGpPWpGaD
Venlafaxine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000154	0.00481	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling Pathways—HCAR2—psoriasis	0.000153	0.00481	CbGpPWpGaD
Venlafaxine—NPY1R—GPCR downstream signaling—CCL20—psoriasis	0.000149	0.00466	CbGpPWpGaD
Venlafaxine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000147	0.00462	CbGpPWpGaD
Venlafaxine—SLC6A3—Dopaminergic Neurogenesis—STAT3—psoriasis	0.000146	0.00458	CbGpPWpGaD
Venlafaxine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000145	0.00456	CbGpPWpGaD
Venlafaxine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000145	0.00455	CbGpPWpGaD
Venlafaxine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000143	0.0045	CbGpPWpGaD
Venlafaxine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000143	0.00448	CbGpPWpGaD
Venlafaxine—NPY1R—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000139	0.00435	CbGpPWpGaD
Venlafaxine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000136	0.00425	CbGpPWpGaD
Venlafaxine—SLC6A2—Monoamine Transport—TNF—psoriasis	0.000136	0.00425	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling by GPCR—CCL20—psoriasis	0.000135	0.00423	CbGpPWpGaD
Venlafaxine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000134	0.00422	CbGpPWpGaD
Venlafaxine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000134	0.00419	CbGpPWpGaD
Venlafaxine—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000134	0.00419	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling Pathways—TAGAP—psoriasis	0.000133	0.00417	CbGpPWpGaD
Venlafaxine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000133	0.00416	CbGpPWpGaD
Venlafaxine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000132	0.00412	CbGpPWpGaD
Venlafaxine—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000125	0.00391	CbGpPWpGaD
Venlafaxine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000123	0.00385	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000122	0.00384	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—IL13—psoriasis	0.000122	0.00381	CbGpPWpGaD
Venlafaxine—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	0.00012	0.00377	CbGpPWpGaD
Venlafaxine—SLC6A3—Monoamine Transport—TNF—psoriasis	0.00012	0.00376	CbGpPWpGaD
Venlafaxine—NPY1R—G alpha (i) signalling events—CXCL8—psoriasis	0.000117	0.00367	CbGpPWpGaD
Venlafaxine—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	0.000117	0.00365	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000112	0.00351	CbGpPWpGaD
Venlafaxine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000107	0.00336	CbGpPWpGaD
Venlafaxine—SLC6A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000107	0.00334	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000104	0.00326	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000102	0.00318	CbGpPWpGaD
Venlafaxine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.0001	0.00313	CbGpPWpGaD
Venlafaxine—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	9.49e-05	0.00298	CbGpPWpGaD
Venlafaxine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.46e-05	0.00297	CbGpPWpGaD
Venlafaxine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	9.32e-05	0.00292	CbGpPWpGaD
Venlafaxine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.87e-05	0.00278	CbGpPWpGaD
Venlafaxine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.75e-05	0.00274	CbGpPWpGaD
Venlafaxine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	8.5e-05	0.00267	CbGpPWpGaD
Venlafaxine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.41e-05	0.00264	CbGpPWpGaD
Venlafaxine—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	8.26e-05	0.00259	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling Pathways—CCL20—psoriasis	7.97e-05	0.0025	CbGpPWpGaD
Venlafaxine—SLC6A4—Circadian rythm related genes—LEP—psoriasis	7.83e-05	0.00246	CbGpPWpGaD
Venlafaxine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	7.82e-05	0.00245	CbGpPWpGaD
Venlafaxine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.65e-05	0.0024	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—IL10—psoriasis	7.61e-05	0.00239	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—IL4—psoriasis	7.4e-05	0.00232	CbGpPWpGaD
Venlafaxine—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	7.3e-05	0.00229	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.24e-05	0.00227	CbGpPWpGaD
Venlafaxine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.23e-05	0.00227	CbGpPWpGaD
Venlafaxine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	7.22e-05	0.00226	CbGpPWpGaD
Venlafaxine—NPY1R—GPCR ligand binding—CXCL8—psoriasis	7.1e-05	0.00222	CbGpPWpGaD
Venlafaxine—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	6.82e-05	0.00214	CbGpPWpGaD
Venlafaxine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.74e-05	0.00211	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.71e-05	0.0021	CbGpPWpGaD
Venlafaxine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.6e-05	0.00207	CbGpPWpGaD
Venlafaxine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	6.38e-05	0.002	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.13e-05	0.00192	CbGpPWpGaD
Venlafaxine—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	6.11e-05	0.00192	CbGpPWpGaD
Venlafaxine—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	5.93e-05	0.00186	CbGpPWpGaD
Venlafaxine—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	5.83e-05	0.00183	CbGpPWpGaD
Venlafaxine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.71e-05	0.00179	CbGpPWpGaD
Venlafaxine—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	5.41e-05	0.0017	CbGpPWpGaD
Venlafaxine—ABCG2—Metabolism—NDUFA5—psoriasis	5.36e-05	0.00168	CbGpPWpGaD
Venlafaxine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.18e-05	0.00162	CbGpPWpGaD
Venlafaxine—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	5.16e-05	0.00162	CbGpPWpGaD
Venlafaxine—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	4.98e-05	0.00156	CbGpPWpGaD
Venlafaxine—SLC6A4—Circadian rythm related genes—JUN—psoriasis	4.84e-05	0.00152	CbGpPWpGaD
Venlafaxine—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	4.75e-05	0.00149	CbGpPWpGaD
Venlafaxine—ABCG2—Metabolism—CYP2S1—psoriasis	4.55e-05	0.00143	CbGpPWpGaD
Venlafaxine—Feeling abnormal—Mycophenolate mofetil—psoriasis	4.55e-05	0.000129	CcSEcCtD
Venlafaxine—Insomnia—Hydrocortisone—psoriasis	4.55e-05	0.000129	CcSEcCtD
Venlafaxine—Hypertension—Betamethasone—psoriasis	4.55e-05	0.000129	CcSEcCtD
Venlafaxine—Hypertension—Dexamethasone—psoriasis	4.55e-05	0.000129	CcSEcCtD
Venlafaxine—Paraesthesia—Hydrocortisone—psoriasis	4.52e-05	0.000128	CcSEcCtD
Venlafaxine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	4.52e-05	0.000128	CcSEcCtD
Venlafaxine—Urticaria—Cyclosporine—psoriasis	4.5e-05	0.000128	CcSEcCtD
Venlafaxine—Myalgia—Betamethasone—psoriasis	4.49e-05	0.000127	CcSEcCtD
Venlafaxine—Myalgia—Dexamethasone—psoriasis	4.49e-05	0.000127	CcSEcCtD
Venlafaxine—Abdominal pain—Cyclosporine—psoriasis	4.48e-05	0.000127	CcSEcCtD
Venlafaxine—Body temperature increased—Cyclosporine—psoriasis	4.48e-05	0.000127	CcSEcCtD
Venlafaxine—ABCB1—Allograft Rejection—IFNG—psoriasis	4.47e-05	0.0014	CbGpPWpGaD
Venlafaxine—Anxiety—Dexamethasone—psoriasis	4.47e-05	0.000127	CcSEcCtD
Venlafaxine—Anxiety—Betamethasone—psoriasis	4.47e-05	0.000127	CcSEcCtD
Venlafaxine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.47e-05	0.0014	CbGpPWpGaD
Venlafaxine—Vomiting—Mycophenolic acid—psoriasis	4.45e-05	0.000126	CcSEcCtD
Venlafaxine—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	4.44e-05	0.00139	CbGpPWpGaD
Venlafaxine—Discomfort—Betamethasone—psoriasis	4.43e-05	0.000126	CcSEcCtD
Venlafaxine—Discomfort—Dexamethasone—psoriasis	4.43e-05	0.000126	CcSEcCtD
Venlafaxine—Dyspepsia—Hydrocortisone—psoriasis	4.43e-05	0.000126	CcSEcCtD
Venlafaxine—Haemoglobin—Methotrexate—psoriasis	4.43e-05	0.000126	CcSEcCtD
Venlafaxine—Rash—Mycophenolic acid—psoriasis	4.41e-05	0.000125	CcSEcCtD
Venlafaxine—Dermatitis—Mycophenolic acid—psoriasis	4.41e-05	0.000125	CcSEcCtD
Venlafaxine—Pain—Prednisolone—psoriasis	4.41e-05	0.000125	CcSEcCtD
Venlafaxine—Haemorrhage—Methotrexate—psoriasis	4.4e-05	0.000125	CcSEcCtD
Venlafaxine—Hepatitis—Methotrexate—psoriasis	4.4e-05	0.000125	CcSEcCtD
Venlafaxine—Urticaria—Mycophenolate mofetil—psoriasis	4.39e-05	0.000125	CcSEcCtD
Venlafaxine—NPY1R—Signaling Pathways—SOCS1—psoriasis	4.39e-05	0.00138	CbGpPWpGaD
Venlafaxine—Headache—Mycophenolic acid—psoriasis	4.39e-05	0.000125	CcSEcCtD
Venlafaxine—Decreased appetite—Hydrocortisone—psoriasis	4.38e-05	0.000124	CcSEcCtD
Venlafaxine—Pharyngitis—Methotrexate—psoriasis	4.37e-05	0.000124	CcSEcCtD
Venlafaxine—Body temperature increased—Mycophenolate mofetil—psoriasis	4.37e-05	0.000124	CcSEcCtD
Venlafaxine—Abdominal pain—Mycophenolate mofetil—psoriasis	4.37e-05	0.000124	CcSEcCtD
Venlafaxine—Fatigue—Hydrocortisone—psoriasis	4.34e-05	0.000123	CcSEcCtD
Venlafaxine—Vision blurred—Prednisone—psoriasis	4.32e-05	0.000123	CcSEcCtD
Venlafaxine—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.32e-05	0.000123	CcSEcCtD
Venlafaxine—Pain—Hydrocortisone—psoriasis	4.3e-05	0.000122	CcSEcCtD
Venlafaxine—Oedema—Betamethasone—psoriasis	4.3e-05	0.000122	CcSEcCtD
Venlafaxine—Anaphylactic shock—Dexamethasone—psoriasis	4.3e-05	0.000122	CcSEcCtD
Venlafaxine—Anaphylactic shock—Betamethasone—psoriasis	4.3e-05	0.000122	CcSEcCtD
Venlafaxine—Oedema—Dexamethasone—psoriasis	4.3e-05	0.000122	CcSEcCtD
Venlafaxine—Insomnia—Triamcinolone—psoriasis	4.29e-05	0.000122	CcSEcCtD
Venlafaxine—Infection—Betamethasone—psoriasis	4.27e-05	0.000121	CcSEcCtD
Venlafaxine—Infection—Dexamethasone—psoriasis	4.27e-05	0.000121	CcSEcCtD
Venlafaxine—Ill-defined disorder—Prednisone—psoriasis	4.26e-05	0.000121	CcSEcCtD
Venlafaxine—Paraesthesia—Triamcinolone—psoriasis	4.26e-05	0.000121	CcSEcCtD
Venlafaxine—Feeling abnormal—Prednisolone—psoriasis	4.25e-05	0.000121	CcSEcCtD
Venlafaxine—Visual impairment—Methotrexate—psoriasis	4.24e-05	0.000121	CcSEcCtD
Venlafaxine—Anaemia—Prednisone—psoriasis	4.24e-05	0.00012	CcSEcCtD
Venlafaxine—Shock—Dexamethasone—psoriasis	4.23e-05	0.00012	CcSEcCtD
Venlafaxine—Shock—Betamethasone—psoriasis	4.23e-05	0.00012	CcSEcCtD
Venlafaxine—Dyspnoea—Triamcinolone—psoriasis	4.22e-05	0.00012	CcSEcCtD
Venlafaxine—Agitation—Prednisone—psoriasis	4.22e-05	0.00012	CcSEcCtD
Venlafaxine—Thrombocytopenia—Betamethasone—psoriasis	4.21e-05	0.00012	CcSEcCtD
Venlafaxine—Thrombocytopenia—Dexamethasone—psoriasis	4.21e-05	0.00012	CcSEcCtD
Venlafaxine—Tachycardia—Betamethasone—psoriasis	4.2e-05	0.000119	CcSEcCtD
Venlafaxine—Tachycardia—Dexamethasone—psoriasis	4.2e-05	0.000119	CcSEcCtD
Venlafaxine—Angioedema—Prednisone—psoriasis	4.19e-05	0.000119	CcSEcCtD
Venlafaxine—NPY1R—Signaling by GPCR—TYK2—psoriasis	4.18e-05	0.00131	CbGpPWpGaD
Venlafaxine—Hypersensitivity—Cyclosporine—psoriasis	4.17e-05	0.000118	CcSEcCtD
Venlafaxine—Dyspepsia—Triamcinolone—psoriasis	4.17e-05	0.000118	CcSEcCtD
Venlafaxine—Erythema multiforme—Methotrexate—psoriasis	4.16e-05	0.000118	CcSEcCtD
Venlafaxine—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.16e-05	0.0013	CbGpPWpGaD
Venlafaxine—Nausea—Mycophenolic acid—psoriasis	4.16e-05	0.000118	CcSEcCtD
Venlafaxine—Hyperhidrosis—Dexamethasone—psoriasis	4.16e-05	0.000118	CcSEcCtD
Venlafaxine—Hyperhidrosis—Betamethasone—psoriasis	4.16e-05	0.000118	CcSEcCtD
Venlafaxine—Feeling abnormal—Hydrocortisone—psoriasis	4.15e-05	0.000118	CcSEcCtD
Venlafaxine—Malaise—Prednisone—psoriasis	4.14e-05	0.000118	CcSEcCtD
Venlafaxine—Vertigo—Prednisone—psoriasis	4.12e-05	0.000117	CcSEcCtD
Venlafaxine—Gastrointestinal pain—Hydrocortisone—psoriasis	4.12e-05	0.000117	CcSEcCtD
Venlafaxine—Syncope—Prednisone—psoriasis	4.11e-05	0.000117	CcSEcCtD
Venlafaxine—Tinnitus—Methotrexate—psoriasis	4.11e-05	0.000117	CcSEcCtD
Venlafaxine—Anorexia—Betamethasone—psoriasis	4.1e-05	0.000116	CcSEcCtD
Venlafaxine—Anorexia—Dexamethasone—psoriasis	4.1e-05	0.000116	CcSEcCtD
Venlafaxine—Urticaria—Prednisolone—psoriasis	4.09e-05	0.000116	CcSEcCtD
Venlafaxine—Cardiac disorder—Methotrexate—psoriasis	4.09e-05	0.000116	CcSEcCtD
Venlafaxine—Fatigue—Triamcinolone—psoriasis	4.09e-05	0.000116	CcSEcCtD
Venlafaxine—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.07e-05	0.000116	CcSEcCtD
Venlafaxine—Asthenia—Cyclosporine—psoriasis	4.06e-05	0.000115	CcSEcCtD
Venlafaxine—Pain—Triamcinolone—psoriasis	4.05e-05	0.000115	CcSEcCtD
Venlafaxine—Loss of consciousness—Prednisone—psoriasis	4.03e-05	0.000115	CcSEcCtD
Venlafaxine—Hypotension—Dexamethasone—psoriasis	4.02e-05	0.000114	CcSEcCtD
Venlafaxine—Hypotension—Betamethasone—psoriasis	4.02e-05	0.000114	CcSEcCtD
Venlafaxine—NPY1R—GPCR downstream signaling—CXCL8—psoriasis	4.01e-05	0.00126	CbGpPWpGaD
Venlafaxine—Pruritus—Cyclosporine—psoriasis	4.01e-05	0.000114	CcSEcCtD
Venlafaxine—Urticaria—Hydrocortisone—psoriasis	4e-05	0.000114	CcSEcCtD
Venlafaxine—Body temperature increased—Hydrocortisone—psoriasis	3.98e-05	0.000113	CcSEcCtD
Venlafaxine—Abdominal pain—Hydrocortisone—psoriasis	3.98e-05	0.000113	CcSEcCtD
Venlafaxine—Convulsion—Prednisone—psoriasis	3.98e-05	0.000113	CcSEcCtD
Venlafaxine—Asthenia—Mycophenolate mofetil—psoriasis	3.96e-05	0.000113	CcSEcCtD
Venlafaxine—Hypertension—Prednisone—psoriasis	3.96e-05	0.000113	CcSEcCtD
Venlafaxine—Chills—Methotrexate—psoriasis	3.95e-05	0.000112	CcSEcCtD
Venlafaxine—CYP2B6—Metabolism—NDUFA5—psoriasis	3.93e-05	0.00123	CbGpPWpGaD
Venlafaxine—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.92e-05	0.000111	CcSEcCtD
Venlafaxine—Musculoskeletal discomfort—Betamethasone—psoriasis	3.92e-05	0.000111	CcSEcCtD
Venlafaxine—Pruritus—Mycophenolate mofetil—psoriasis	3.91e-05	0.000111	CcSEcCtD
Venlafaxine—Arthralgia—Prednisone—psoriasis	3.91e-05	0.000111	CcSEcCtD
Venlafaxine—Myalgia—Prednisone—psoriasis	3.91e-05	0.000111	CcSEcCtD
Venlafaxine—Feeling abnormal—Triamcinolone—psoriasis	3.91e-05	0.000111	CcSEcCtD
Venlafaxine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.9e-05	0.00122	CbGpPWpGaD
Venlafaxine—Anxiety—Prednisone—psoriasis	3.89e-05	0.000111	CcSEcCtD
Venlafaxine—Alopecia—Methotrexate—psoriasis	3.89e-05	0.000111	CcSEcCtD
Venlafaxine—Insomnia—Betamethasone—psoriasis	3.89e-05	0.00011	CcSEcCtD
Venlafaxine—Insomnia—Dexamethasone—psoriasis	3.89e-05	0.00011	CcSEcCtD
Venlafaxine—Diarrhoea—Cyclosporine—psoriasis	3.87e-05	0.00011	CcSEcCtD
Venlafaxine—Paraesthesia—Dexamethasone—psoriasis	3.86e-05	0.00011	CcSEcCtD
Venlafaxine—Paraesthesia—Betamethasone—psoriasis	3.86e-05	0.00011	CcSEcCtD
Venlafaxine—Discomfort—Prednisone—psoriasis	3.86e-05	0.00011	CcSEcCtD
Venlafaxine—Erythema—Methotrexate—psoriasis	3.83e-05	0.000109	CcSEcCtD
Venlafaxine—Hypersensitivity—Prednisolone—psoriasis	3.8e-05	0.000108	CcSEcCtD
Venlafaxine—Dyspepsia—Betamethasone—psoriasis	3.79e-05	0.000107	CcSEcCtD
Venlafaxine—Dyspepsia—Dexamethasone—psoriasis	3.79e-05	0.000107	CcSEcCtD
Venlafaxine—Diarrhoea—Mycophenolate mofetil—psoriasis	3.78e-05	0.000107	CcSEcCtD
Venlafaxine—Urticaria—Triamcinolone—psoriasis	3.76e-05	0.000107	CcSEcCtD
Venlafaxine—Dysgeusia—Methotrexate—psoriasis	3.76e-05	0.000107	CcSEcCtD
Venlafaxine—Body temperature increased—Triamcinolone—psoriasis	3.75e-05	0.000106	CcSEcCtD
Venlafaxine—Dizziness—Cyclosporine—psoriasis	3.74e-05	0.000106	CcSEcCtD
Venlafaxine—Oedema—Prednisone—psoriasis	3.74e-05	0.000106	CcSEcCtD
Venlafaxine—Anaphylactic shock—Prednisone—psoriasis	3.74e-05	0.000106	CcSEcCtD
Venlafaxine—Decreased appetite—Betamethasone—psoriasis	3.74e-05	0.000106	CcSEcCtD
Venlafaxine—Decreased appetite—Dexamethasone—psoriasis	3.74e-05	0.000106	CcSEcCtD
Venlafaxine—Infection—Prednisone—psoriasis	3.72e-05	0.000106	CcSEcCtD
Venlafaxine—Back pain—Methotrexate—psoriasis	3.71e-05	0.000105	CcSEcCtD
Venlafaxine—Hypersensitivity—Hydrocortisone—psoriasis	3.71e-05	0.000105	CcSEcCtD
Venlafaxine—Fatigue—Dexamethasone—psoriasis	3.71e-05	0.000105	CcSEcCtD
Venlafaxine—Fatigue—Betamethasone—psoriasis	3.71e-05	0.000105	CcSEcCtD
Venlafaxine—Shock—Prednisone—psoriasis	3.68e-05	0.000105	CcSEcCtD
Venlafaxine—Pain—Dexamethasone—psoriasis	3.68e-05	0.000104	CcSEcCtD
Venlafaxine—Pain—Betamethasone—psoriasis	3.68e-05	0.000104	CcSEcCtD
Venlafaxine—Tachycardia—Prednisone—psoriasis	3.65e-05	0.000104	CcSEcCtD
Venlafaxine—Dizziness—Mycophenolate mofetil—psoriasis	3.65e-05	0.000104	CcSEcCtD
Venlafaxine—NPY1R—Signaling by GPCR—CXCL8—psoriasis	3.64e-05	0.00114	CbGpPWpGaD
Venlafaxine—Hyperhidrosis—Prednisone—psoriasis	3.62e-05	0.000103	CcSEcCtD
Venlafaxine—Vision blurred—Methotrexate—psoriasis	3.61e-05	0.000103	CcSEcCtD
Venlafaxine—Asthenia—Hydrocortisone—psoriasis	3.61e-05	0.000103	CcSEcCtD
Venlafaxine—Vomiting—Cyclosporine—psoriasis	3.6e-05	0.000102	CcSEcCtD
Venlafaxine—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	3.58e-05	0.00112	CbGpPWpGaD
Venlafaxine—Rash—Cyclosporine—psoriasis	3.57e-05	0.000101	CcSEcCtD
Venlafaxine—Anorexia—Prednisone—psoriasis	3.57e-05	0.000101	CcSEcCtD
Venlafaxine—Dermatitis—Cyclosporine—psoriasis	3.57e-05	0.000101	CcSEcCtD
Venlafaxine—Pruritus—Hydrocortisone—psoriasis	3.56e-05	0.000101	CcSEcCtD
Venlafaxine—Ill-defined disorder—Methotrexate—psoriasis	3.56e-05	0.000101	CcSEcCtD
Venlafaxine—Headache—Cyclosporine—psoriasis	3.55e-05	0.000101	CcSEcCtD
Venlafaxine—Anaemia—Methotrexate—psoriasis	3.54e-05	0.000101	CcSEcCtD
Venlafaxine—Feeling abnormal—Betamethasone—psoriasis	3.54e-05	0.000101	CcSEcCtD
Venlafaxine—Feeling abnormal—Dexamethasone—psoriasis	3.54e-05	0.000101	CcSEcCtD
Venlafaxine—Gastrointestinal pain—Dexamethasone—psoriasis	3.52e-05	9.99e-05	CcSEcCtD
Venlafaxine—Gastrointestinal pain—Betamethasone—psoriasis	3.52e-05	9.99e-05	CcSEcCtD
Venlafaxine—Vomiting—Mycophenolate mofetil—psoriasis	3.51e-05	9.98e-05	CcSEcCtD
Venlafaxine—Hypersensitivity—Triamcinolone—psoriasis	3.49e-05	9.92e-05	CcSEcCtD
Venlafaxine—Rash—Mycophenolate mofetil—psoriasis	3.48e-05	9.89e-05	CcSEcCtD
Venlafaxine—Dermatitis—Mycophenolate mofetil—psoriasis	3.48e-05	9.88e-05	CcSEcCtD
Venlafaxine—Headache—Mycophenolate mofetil—psoriasis	3.46e-05	9.83e-05	CcSEcCtD
Venlafaxine—Malaise—Methotrexate—psoriasis	3.46e-05	9.82e-05	CcSEcCtD
Venlafaxine—Vertigo—Methotrexate—psoriasis	3.45e-05	9.78e-05	CcSEcCtD
Venlafaxine—Diarrhoea—Hydrocortisone—psoriasis	3.44e-05	9.78e-05	CcSEcCtD
Venlafaxine—Leukopenia—Methotrexate—psoriasis	3.43e-05	9.75e-05	CcSEcCtD
Venlafaxine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.43e-05	0.00107	CbGpPWpGaD
Venlafaxine—Urticaria—Dexamethasone—psoriasis	3.42e-05	9.7e-05	CcSEcCtD
Venlafaxine—Urticaria—Betamethasone—psoriasis	3.42e-05	9.7e-05	CcSEcCtD
Venlafaxine—Musculoskeletal discomfort—Prednisone—psoriasis	3.41e-05	9.69e-05	CcSEcCtD
Venlafaxine—Dizziness—Prednisolone—psoriasis	3.41e-05	9.68e-05	CcSEcCtD
Venlafaxine—Asthenia—Triamcinolone—psoriasis	3.4e-05	9.66e-05	CcSEcCtD
Venlafaxine—Body temperature increased—Dexamethasone—psoriasis	3.4e-05	9.65e-05	CcSEcCtD
Venlafaxine—Body temperature increased—Betamethasone—psoriasis	3.4e-05	9.65e-05	CcSEcCtD
Venlafaxine—Abdominal pain—Dexamethasone—psoriasis	3.4e-05	9.65e-05	CcSEcCtD
Venlafaxine—Abdominal pain—Betamethasone—psoriasis	3.4e-05	9.65e-05	CcSEcCtD
Venlafaxine—Insomnia—Prednisone—psoriasis	3.39e-05	9.62e-05	CcSEcCtD
Venlafaxine—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.38e-05	0.00106	CbGpPWpGaD
Venlafaxine—Nausea—Cyclosporine—psoriasis	3.36e-05	9.55e-05	CcSEcCtD
Venlafaxine—Paraesthesia—Prednisone—psoriasis	3.36e-05	9.55e-05	CcSEcCtD
Venlafaxine—Pruritus—Triamcinolone—psoriasis	3.35e-05	9.52e-05	CcSEcCtD
Venlafaxine—Cough—Methotrexate—psoriasis	3.35e-05	9.5e-05	CcSEcCtD
Venlafaxine—CYP2B6—Metabolism—CYP2S1—psoriasis	3.34e-05	0.00105	CbGpPWpGaD
Venlafaxine—Dizziness—Hydrocortisone—psoriasis	3.33e-05	9.45e-05	CcSEcCtD
Venlafaxine—Convulsion—Methotrexate—psoriasis	3.32e-05	9.44e-05	CcSEcCtD
Venlafaxine—Dyspepsia—Prednisone—psoriasis	3.3e-05	9.36e-05	CcSEcCtD
Venlafaxine—Nausea—Mycophenolate mofetil—psoriasis	3.28e-05	9.32e-05	CcSEcCtD
Venlafaxine—Myalgia—Methotrexate—psoriasis	3.26e-05	9.27e-05	CcSEcCtD
Venlafaxine—Chest pain—Methotrexate—psoriasis	3.26e-05	9.27e-05	CcSEcCtD
Venlafaxine—Arthralgia—Methotrexate—psoriasis	3.26e-05	9.27e-05	CcSEcCtD
Venlafaxine—Decreased appetite—Prednisone—psoriasis	3.26e-05	9.24e-05	CcSEcCtD
Venlafaxine—Rash—Prednisolone—psoriasis	3.25e-05	9.23e-05	CcSEcCtD
Venlafaxine—Dermatitis—Prednisolone—psoriasis	3.25e-05	9.22e-05	CcSEcCtD
Venlafaxine—NPY1R—Signaling Pathways—LEP—psoriasis	3.24e-05	0.00101	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling Pathways—APOE—psoriasis	3.24e-05	0.00101	CbGpPWpGaD
Venlafaxine—Fatigue—Prednisone—psoriasis	3.23e-05	9.17e-05	CcSEcCtD
Venlafaxine—Headache—Prednisolone—psoriasis	3.23e-05	9.17e-05	CcSEcCtD
Venlafaxine—Discomfort—Methotrexate—psoriasis	3.23e-05	9.16e-05	CcSEcCtD
Venlafaxine—Constipation—Prednisone—psoriasis	3.2e-05	9.09e-05	CcSEcCtD
Venlafaxine—Vomiting—Hydrocortisone—psoriasis	3.2e-05	9.09e-05	CcSEcCtD
Venlafaxine—SLC6A4—Circadian rythm related genes—TP53—psoriasis	3.19e-05	0.001	CbGpPWpGaD
Venlafaxine—Rash—Hydrocortisone—psoriasis	3.17e-05	9.01e-05	CcSEcCtD
Venlafaxine—Dermatitis—Hydrocortisone—psoriasis	3.17e-05	9e-05	CcSEcCtD
Venlafaxine—Confusional state—Methotrexate—psoriasis	3.16e-05	8.96e-05	CcSEcCtD
Venlafaxine—Headache—Hydrocortisone—psoriasis	3.15e-05	8.95e-05	CcSEcCtD
Venlafaxine—Dizziness—Triamcinolone—psoriasis	3.13e-05	8.9e-05	CcSEcCtD
Venlafaxine—Anaphylactic shock—Methotrexate—psoriasis	3.13e-05	8.89e-05	CcSEcCtD
Venlafaxine—Infection—Methotrexate—psoriasis	3.11e-05	8.83e-05	CcSEcCtD
Venlafaxine—Feeling abnormal—Prednisone—psoriasis	3.09e-05	8.76e-05	CcSEcCtD
Venlafaxine—Asthenia—Betamethasone—psoriasis	3.09e-05	8.76e-05	CcSEcCtD
Venlafaxine—Asthenia—Dexamethasone—psoriasis	3.09e-05	8.76e-05	CcSEcCtD
Venlafaxine—Thrombocytopenia—Methotrexate—psoriasis	3.06e-05	8.7e-05	CcSEcCtD
Venlafaxine—Gastrointestinal pain—Prednisone—psoriasis	3.06e-05	8.7e-05	CcSEcCtD
Venlafaxine—Nausea—Prednisolone—psoriasis	3.06e-05	8.69e-05	CcSEcCtD
Venlafaxine—Pruritus—Dexamethasone—psoriasis	3.04e-05	8.64e-05	CcSEcCtD
Venlafaxine—Pruritus—Betamethasone—psoriasis	3.04e-05	8.64e-05	CcSEcCtD
Venlafaxine—Hyperhidrosis—Methotrexate—psoriasis	3.03e-05	8.59e-05	CcSEcCtD
Venlafaxine—NPY1R—Signaling Pathways—NFKBIA—psoriasis	3.02e-05	0.000946	CbGpPWpGaD
Venlafaxine—Vomiting—Triamcinolone—psoriasis	3.01e-05	8.56e-05	CcSEcCtD
Venlafaxine—Nausea—Hydrocortisone—psoriasis	2.99e-05	8.49e-05	CcSEcCtD
Venlafaxine—Rash—Triamcinolone—psoriasis	2.99e-05	8.49e-05	CcSEcCtD
Venlafaxine—Dermatitis—Triamcinolone—psoriasis	2.99e-05	8.48e-05	CcSEcCtD
Venlafaxine—Anorexia—Methotrexate—psoriasis	2.98e-05	8.47e-05	CcSEcCtD
Venlafaxine—Urticaria—Prednisone—psoriasis	2.97e-05	8.45e-05	CcSEcCtD
Venlafaxine—Headache—Triamcinolone—psoriasis	2.97e-05	8.43e-05	CcSEcCtD
Venlafaxine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.97e-05	0.00093	CbGpPWpGaD
Venlafaxine—Abdominal pain—Prednisone—psoriasis	2.96e-05	8.41e-05	CcSEcCtD
Venlafaxine—Body temperature increased—Prednisone—psoriasis	2.96e-05	8.41e-05	CcSEcCtD
Venlafaxine—Diarrhoea—Betamethasone—psoriasis	2.94e-05	8.36e-05	CcSEcCtD
Venlafaxine—Diarrhoea—Dexamethasone—psoriasis	2.94e-05	8.36e-05	CcSEcCtD
Venlafaxine—Hypotension—Methotrexate—psoriasis	2.92e-05	8.3e-05	CcSEcCtD
Venlafaxine—SLC6A4—Circadian rythm related genes—IL6—psoriasis	2.92e-05	0.000917	CbGpPWpGaD
Venlafaxine—ABCB1—Allograft Rejection—TNF—psoriasis	2.9e-05	0.000908	CbGpPWpGaD
Venlafaxine—ABCB1—Metabolism—NDUFA5—psoriasis	2.9e-05	0.000908	CbGpPWpGaD
Venlafaxine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.88e-05	0.000902	CbGpPWpGaD
Venlafaxine—Musculoskeletal discomfort—Methotrexate—psoriasis	2.85e-05	8.1e-05	CcSEcCtD
Venlafaxine—Dizziness—Betamethasone—psoriasis	2.84e-05	8.08e-05	CcSEcCtD
Venlafaxine—Dizziness—Dexamethasone—psoriasis	2.84e-05	8.08e-05	CcSEcCtD
Venlafaxine—Insomnia—Methotrexate—psoriasis	2.83e-05	8.04e-05	CcSEcCtD
Venlafaxine—Nausea—Triamcinolone—psoriasis	2.81e-05	7.99e-05	CcSEcCtD
Venlafaxine—Paraesthesia—Methotrexate—psoriasis	2.81e-05	7.98e-05	CcSEcCtD
Venlafaxine—Dyspnoea—Methotrexate—psoriasis	2.79e-05	7.92e-05	CcSEcCtD
Venlafaxine—Somnolence—Methotrexate—psoriasis	2.78e-05	7.9e-05	CcSEcCtD
Venlafaxine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.77e-05	0.000867	CbGpPWpGaD
Venlafaxine—Hypersensitivity—Prednisone—psoriasis	2.76e-05	7.84e-05	CcSEcCtD
Venlafaxine—Dyspepsia—Methotrexate—psoriasis	2.75e-05	7.82e-05	CcSEcCtD
Venlafaxine—Vomiting—Dexamethasone—psoriasis	2.73e-05	7.76e-05	CcSEcCtD
Venlafaxine—Vomiting—Betamethasone—psoriasis	2.73e-05	7.76e-05	CcSEcCtD
Venlafaxine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.73e-05	0.000855	CbGpPWpGaD
Venlafaxine—Decreased appetite—Methotrexate—psoriasis	2.72e-05	7.73e-05	CcSEcCtD
Venlafaxine—Rash—Betamethasone—psoriasis	2.71e-05	7.7e-05	CcSEcCtD
Venlafaxine—Rash—Dexamethasone—psoriasis	2.71e-05	7.7e-05	CcSEcCtD
Venlafaxine—Dermatitis—Betamethasone—psoriasis	2.71e-05	7.69e-05	CcSEcCtD
Venlafaxine—Dermatitis—Dexamethasone—psoriasis	2.71e-05	7.69e-05	CcSEcCtD
Venlafaxine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.7e-05	0.000848	CbGpPWpGaD
Venlafaxine—Fatigue—Methotrexate—psoriasis	2.7e-05	7.66e-05	CcSEcCtD
Venlafaxine—Headache—Betamethasone—psoriasis	2.69e-05	7.65e-05	CcSEcCtD
Venlafaxine—Headache—Dexamethasone—psoriasis	2.69e-05	7.65e-05	CcSEcCtD
Venlafaxine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.69e-05	0.000843	CbGpPWpGaD
Venlafaxine—Asthenia—Prednisone—psoriasis	2.69e-05	7.63e-05	CcSEcCtD
Venlafaxine—Pain—Methotrexate—psoriasis	2.68e-05	7.6e-05	CcSEcCtD
Venlafaxine—Pruritus—Prednisone—psoriasis	2.65e-05	7.52e-05	CcSEcCtD
Venlafaxine—Feeling abnormal—Methotrexate—psoriasis	2.58e-05	7.32e-05	CcSEcCtD
Venlafaxine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.57e-05	0.000805	CbGpPWpGaD
Venlafaxine—Diarrhoea—Prednisone—psoriasis	2.56e-05	7.28e-05	CcSEcCtD
Venlafaxine—Gastrointestinal pain—Methotrexate—psoriasis	2.56e-05	7.27e-05	CcSEcCtD
Venlafaxine—Nausea—Dexamethasone—psoriasis	2.55e-05	7.25e-05	CcSEcCtD
Venlafaxine—Nausea—Betamethasone—psoriasis	2.55e-05	7.25e-05	CcSEcCtD
Venlafaxine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.52e-05	0.000791	CbGpPWpGaD
Venlafaxine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.52e-05	0.000791	CbGpPWpGaD
Venlafaxine—Urticaria—Methotrexate—psoriasis	2.49e-05	7.06e-05	CcSEcCtD
Venlafaxine—Dizziness—Prednisone—psoriasis	2.48e-05	7.03e-05	CcSEcCtD
Venlafaxine—Abdominal pain—Methotrexate—psoriasis	2.47e-05	7.03e-05	CcSEcCtD
Venlafaxine—Body temperature increased—Methotrexate—psoriasis	2.47e-05	7.03e-05	CcSEcCtD
Venlafaxine—NPY1R—Signaling Pathways—TYK2—psoriasis	2.47e-05	0.000775	CbGpPWpGaD
Venlafaxine—ABCB1—Metabolism—CYP2S1—psoriasis	2.46e-05	0.000772	CbGpPWpGaD
Venlafaxine—Vomiting—Prednisone—psoriasis	2.38e-05	6.76e-05	CcSEcCtD
Venlafaxine—Rash—Prednisone—psoriasis	2.36e-05	6.71e-05	CcSEcCtD
Venlafaxine—Dermatitis—Prednisone—psoriasis	2.36e-05	6.7e-05	CcSEcCtD
Venlafaxine—Headache—Prednisone—psoriasis	2.35e-05	6.66e-05	CcSEcCtD
Venlafaxine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.32e-05	0.000727	CbGpPWpGaD
Venlafaxine—Hypersensitivity—Methotrexate—psoriasis	2.31e-05	6.55e-05	CcSEcCtD
Venlafaxine—CYP2C9—Metabolism—CYP2S1—psoriasis	2.3e-05	0.000721	CbGpPWpGaD
Venlafaxine—Asthenia—Methotrexate—psoriasis	2.25e-05	6.38e-05	CcSEcCtD
Venlafaxine—Nausea—Prednisone—psoriasis	2.22e-05	6.32e-05	CcSEcCtD
Venlafaxine—ABCG2—Metabolism—CARM1—psoriasis	2.22e-05	0.000697	CbGpPWpGaD
Venlafaxine—Pruritus—Methotrexate—psoriasis	2.21e-05	6.29e-05	CcSEcCtD
Venlafaxine—NPY1R—Signaling Pathways—CXCL8—psoriasis	2.15e-05	0.000674	CbGpPWpGaD
Venlafaxine—Diarrhoea—Methotrexate—psoriasis	2.14e-05	6.08e-05	CcSEcCtD
Venlafaxine—Dizziness—Methotrexate—psoriasis	2.07e-05	5.88e-05	CcSEcCtD
Venlafaxine—NPY1R—Signaling by GPCR—IL6—psoriasis	2.05e-05	0.000641	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling Pathways—JUN—psoriasis	2e-05	0.000627	CbGpPWpGaD
Venlafaxine—Vomiting—Methotrexate—psoriasis	1.99e-05	5.65e-05	CcSEcCtD
Venlafaxine—Rash—Methotrexate—psoriasis	1.97e-05	5.6e-05	CcSEcCtD
Venlafaxine—Dermatitis—Methotrexate—psoriasis	1.97e-05	5.6e-05	CcSEcCtD
Venlafaxine—Headache—Methotrexate—psoriasis	1.96e-05	5.57e-05	CcSEcCtD
Venlafaxine—NPY1R—Signaling Pathways—NFKB1—psoriasis	1.93e-05	0.000603	CbGpPWpGaD
Venlafaxine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.91e-05	0.000598	CbGpPWpGaD
Venlafaxine—Nausea—Methotrexate—psoriasis	1.86e-05	5.28e-05	CcSEcCtD
Venlafaxine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.84e-05	0.000576	CbGpPWpGaD
Venlafaxine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.78e-05	0.000559	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling Pathways—VEGFA—psoriasis	1.75e-05	0.000548	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling Pathways—STAT3—psoriasis	1.73e-05	0.000542	CbGpPWpGaD
Venlafaxine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.67e-05	0.000523	CbGpPWpGaD
Venlafaxine—CYP2B6—Metabolism—CARM1—psoriasis	1.63e-05	0.000511	CbGpPWpGaD
Venlafaxine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.52e-05	0.000475	CbGpPWpGaD
Venlafaxine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.43e-05	0.000448	CbGpPWpGaD
Venlafaxine—ABCG2—Metabolism—CAT—psoriasis	1.37e-05	0.000429	CbGpPWpGaD
Venlafaxine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.32e-05	0.000414	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling Pathways—TP53—psoriasis	1.32e-05	0.000414	CbGpPWpGaD
Venlafaxine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.26e-05	0.000395	CbGpPWpGaD
Venlafaxine—CYP2C19—Metabolism—CARM1—psoriasis	1.23e-05	0.000386	CbGpPWpGaD
Venlafaxine—NPY1R—Signaling Pathways—IL6—psoriasis	1.21e-05	0.000379	CbGpPWpGaD
Venlafaxine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.21e-05	0.000378	CbGpPWpGaD
Venlafaxine—ABCB1—Metabolism—CARM1—psoriasis	1.2e-05	0.000377	CbGpPWpGaD
Venlafaxine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.15e-05	0.000361	CbGpPWpGaD
Venlafaxine—CYP2D6—Metabolism—CARM1—psoriasis	1.13e-05	0.000355	CbGpPWpGaD
Venlafaxine—CYP2C9—Metabolism—CARM1—psoriasis	1.12e-05	0.000352	CbGpPWpGaD
Venlafaxine—ABCG2—Metabolism—APOE—psoriasis	1.06e-05	0.000333	CbGpPWpGaD
Venlafaxine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.05e-05	0.000329	CbGpPWpGaD
Venlafaxine—CYP2B6—Metabolism—CAT—psoriasis	1e-05	0.000314	CbGpPWpGaD
Venlafaxine—ABCG2—Metabolism—PPARG—psoriasis	9.26e-06	0.00029	CbGpPWpGaD
Venlafaxine—CYP2B6—Metabolism—APOE—psoriasis	7.79e-06	0.000244	CbGpPWpGaD
Venlafaxine—CYP2C19—Metabolism—CAT—psoriasis	7.58e-06	0.000237	CbGpPWpGaD
Venlafaxine—CYP3A4—Metabolism—CARM1—psoriasis	7.41e-06	0.000232	CbGpPWpGaD
Venlafaxine—ABCB1—Metabolism—CAT—psoriasis	7.39e-06	0.000232	CbGpPWpGaD
Venlafaxine—CYP2D6—Metabolism—CAT—psoriasis	6.97e-06	0.000218	CbGpPWpGaD
Venlafaxine—CYP2C9—Metabolism—CAT—psoriasis	6.91e-06	0.000217	CbGpPWpGaD
Venlafaxine—CYP2B6—Metabolism—PPARG—psoriasis	6.79e-06	0.000213	CbGpPWpGaD
Venlafaxine—CYP2C19—Metabolism—APOE—psoriasis	5.89e-06	0.000185	CbGpPWpGaD
Venlafaxine—ABCB1—Metabolism—APOE—psoriasis	5.75e-06	0.00018	CbGpPWpGaD
Venlafaxine—CYP2D6—Metabolism—APOE—psoriasis	5.41e-06	0.00017	CbGpPWpGaD
Venlafaxine—CYP2C9—Metabolism—APOE—psoriasis	5.37e-06	0.000168	CbGpPWpGaD
Venlafaxine—CYP2C19—Metabolism—PPARG—psoriasis	5.13e-06	0.000161	CbGpPWpGaD
Venlafaxine—ABCB1—Metabolism—PPARG—psoriasis	5e-06	0.000157	CbGpPWpGaD
Venlafaxine—CYP2D6—Metabolism—PPARG—psoriasis	4.72e-06	0.000148	CbGpPWpGaD
Venlafaxine—CYP2C9—Metabolism—PPARG—psoriasis	4.68e-06	0.000147	CbGpPWpGaD
Venlafaxine—CYP3A4—Metabolism—CAT—psoriasis	4.56e-06	0.000143	CbGpPWpGaD
Venlafaxine—CYP3A4—Metabolism—APOE—psoriasis	3.54e-06	0.000111	CbGpPWpGaD
Venlafaxine—CYP3A4—Metabolism—PPARG—psoriasis	3.08e-06	9.67e-05	CbGpPWpGaD
